Yes, currently the only Phase 1 completed, small molecule, rare...

Yes, currently the only Phase 1 completed, small molecule, rare disease drug that Acadia has is NNZ-2591 in Rett syndrome and Fragile-X syndrome. Hopefully these job ads are an indication that Acadia will take action in the not-too-distant future to advance one or both of these programs. Although, as I’ve said before, if Acadia has its eye on acquiring Neuren, it won’t be motivated to advance these programs beforehand.

There is also the possibility that the job ads might relate to advancing the “multiple undisclosed indications”, including rare diseases, which are currently shown as preclinical on the pipeline.

Interestingly these undisclosed rare disease indications first appeared in Acadia’s pipeline in a presentation on 2 August last year, two weeks after the announcement of the much-discussed July 2023 JV and Licence Contract between Acadia and Neuren.